Withdrawn trial sought to test copycat breast cancer drug
NCT ID NCT06884254
Summary
This study aimed to compare a new version of the cancer drug pertuzumab (called EG1206A) against the original version (Perjeta) in people with early-stage HER2-positive breast cancer. Participants would have received drug treatment before surgery, followed by surgery, then more drug treatment afterward. The study was withdrawn before any patients were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Methodist Health System Clinical Research Institute
Dallas, Texas, 75023, United States
Conditions
Explore the condition pages connected to this study.